JP2005521641A - 第ｘａ因子阻害剤としての２−（３−スルホニルアミノ−２−オキソピロリジン−１−イル）プロパンアミド - Google Patents

第ｘａ因子阻害剤としての２−（３−スルホニルアミノ−２−オキソピロリジン−１−イル）プロパンアミド Download PDF

Info

Publication number
JP2005521641A
JP2005521641A JP2003545618A JP2003545618A JP2005521641A JP 2005521641 A JP2005521641 A JP 2005521641A JP 2003545618 A JP2003545618 A JP 2003545618A JP 2003545618 A JP2003545618 A JP 2003545618A JP 2005521641 A JP2005521641 A JP 2005521641A
Authority
JP
Japan
Prior art keywords
amino
sulfonyl
oxopyrrolidin
chloro
naphthyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003545618A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005521641A5 (enExample
Inventor
アラン・デイビッド・ボースウィック
マシュー・キャンベル
チュエン・チャン
ヘンリー・アンダーソン・ケリー
ナイジェル・ポール・キング
サバス・クリーンソウス
アンドリュー・マクマートリー・メイソン
シュテファン・ゼンガー
ポール・ウィリアム・スミス
ナイジェル・スティーブン・ワトソン
ロバート・ジョン・ヤング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2005521641A publication Critical patent/JP2005521641A/ja
Publication of JP2005521641A5 publication Critical patent/JP2005521641A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2003545618A 2001-11-16 2002-11-13 第ｘａ因子阻害剤としての２−（３−スルホニルアミノ−２−オキソピロリジン−１−イル）プロパンアミド Pending JP2005521641A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0127568.4A GB0127568D0 (en) 2001-11-16 2001-11-16 Chemical compounds
PCT/GB2002/005134 WO2003043981A1 (en) 2001-11-16 2002-11-13 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors

Publications (2)

Publication Number Publication Date
JP2005521641A true JP2005521641A (ja) 2005-07-21
JP2005521641A5 JP2005521641A5 (enExample) 2006-01-05

Family

ID=9925931

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003545618A Pending JP2005521641A (ja) 2001-11-16 2002-11-13 第ｘａ因子阻害剤としての２−（３−スルホニルアミノ−２−オキソピロリジン−１−イル）プロパンアミド

Country Status (9)

Country Link
US (1) US7179835B2 (enExample)
EP (1) EP1444201B1 (enExample)
JP (1) JP2005521641A (enExample)
AT (1) ATE372982T1 (enExample)
AU (1) AU2002339158A1 (enExample)
DE (1) DE60222459T2 (enExample)
ES (1) ES2292820T3 (enExample)
GB (1) GB0127568D0 (enExample)
WO (1) WO2003043981A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228552D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Chemical compounds
GB0228533D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Crystalline form
GB0314370D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
TW200524858A (en) 2003-06-19 2005-08-01 Glaxo Group Ltd Chemical compounds
GB0314299D0 (en) 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
GB0314373D0 (en) 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
WO2013057944A1 (ja) 2011-10-19 2013-04-25 興和株式会社 新規なスピロインドリン化合物、及びそれを含有する医薬
SI2989095T1 (sl) * 2013-04-26 2019-03-29 Sanofi Tartratna sol 5-kloro-tiopen-2-karboksilne kisline((s)-2-(metil-3-(2-okso-pirolidin-1-il)-benzensulfonilamino)-3- (4-metil piperazin-1 il)-3-okso-propril)amida

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92011A0 (en) 1988-10-19 1990-07-12 Abbott Lab Heterocyclic peptide renin inhibitors
DE4121947A1 (de) 1991-07-03 1993-01-07 Basf Ag 2-(3-(4-amidino-phenyl))-propionsaeurederivate, ihre herstellung und verwendung
US5703208A (en) * 1994-06-17 1997-12-30 Corvas International, Inc. 3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors
US5932733A (en) 1994-06-17 1999-08-03 Corvas International, Inc. 3-amino-2-oxo-1-piperidineacetic derivatives containing an arginine mimic as enzyme inhibitors
WO1995035311A1 (en) 1994-06-17 1995-12-28 Corvas International, Inc. 3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
WO1997016425A1 (en) 1995-10-30 1997-05-09 Merck & Co., Inc. Novel inhibitors of peptide binding to mhc class ii proteins
CA2268281A1 (en) * 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
US6281227B1 (en) 1996-12-13 2001-08-28 Aventis Pharma Deutschland Gmbh Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
US6602864B1 (en) 1996-12-13 2003-08-05 Aventis Pharma Deutschland Gmbh Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds
EP0944386B1 (en) 1996-12-13 2002-09-18 Aventis Pharmaceuticals Inc. Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
IL135180A0 (en) 1997-09-30 2001-05-20 Daiichi Seiyaku Co Sulfonyl derivatives
ZA988967B (en) 1997-10-03 2000-04-03 Du Pont Pharm Co Lactam metalloprotease inhibitors.
AU756174B2 (en) 1999-02-09 2003-01-09 Bristol-Myers Squibb Company Lactam inhibitors of FXa and method
CA2376961A1 (en) 1999-07-26 2001-02-01 Bristol-Myers Squibb Pharma Company Lactam inhibitors of hepatitis c virus ns3 protease
WO2001019795A1 (en) * 1999-09-13 2001-03-22 3-Dimensional Pharmaceuticals, Inc. Azacycloalkanone serine protease inhibitors
AU2001255408A1 (en) 2000-04-14 2001-10-30 Corvas International, Inc. Tetrahydro-azepinone derivatives as thrombin inhibitors

Also Published As

Publication number Publication date
EP1444201B1 (en) 2007-09-12
ATE372982T1 (de) 2007-09-15
GB0127568D0 (en) 2002-01-09
AU2002339158A1 (en) 2003-06-10
US7179835B2 (en) 2007-02-20
EP1444201A1 (en) 2004-08-11
DE60222459T2 (de) 2008-06-12
WO2003043981A1 (en) 2003-05-30
DE60222459D1 (en) 2007-10-25
ES2292820T3 (es) 2008-03-16
US20050004119A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
JP2013121919A (ja) 血漿カリクレイン阻害剤
JP2003500383A (ja) 第Ｘａ因子阻害剤
CZ251792A3 (en) 1-pyrimidinylacetamide derivatives, process of their preparation and pharmaceutical compositions in which said derivatives are comprised
JP4242274B2 (ja) 因子Ｘａ阻害剤としてのピロリジン誘導体
DE60126143T2 (de) Guanidin- und amidin-verbindungen, und ihre verwendung als faktor xa-inhibitoren
HUP0301670A2 (hu) Xa faktor aktivitását gátló vegyületek, azokat tartalmazó gyógyászati készítmények és alkalmazásuk
AU2009241906A1 (en) Aminopyridine derivatives
CZ301855B6 (cs) N-guanidinoalkylamidy, jejich príprava, použití a farmaceutické smesi, které je obsahují
JP2005521641A (ja) 第ｘａ因子阻害剤としての２−（３−スルホニルアミノ−２−オキソピロリジン−１−イル）プロパンアミド
IE921242A1 (en) Amino acid derivatives
US20060166985A1 (en) Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa
US7482374B2 (en) Pyrrolidine-2-ones as Factor Xa inhibitors
US7329685B2 (en) 1-Phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor Xa inhibitors for the treatment of acute vascular diseases
US7235544B2 (en) 3-sulfonylamino-pyrrolidine-2-one derivatives as inhibitors of factor Xa
KR20060128984A (ko) 유레아 유도체
JP2006527728A (ja) Ｘａ因子の阻害剤としての２−ピロリドン誘導体およびその使用
JP4660197B2 (ja) ２−（５−クロロチエン−２−イル）−ｎ−｛（３ｓ）−１−［（１ｓ）−１−メチル−２−モルホリン−４−イル−２−オキソエチル］−２−オキソピロリジン−３−イル｝エテンスルホンアミドの結晶性誘導体
US20070249705A1 (en) N-(1-(2,3-Dihydro-1H-Inden-5Yl)-2-Oxo-3-Pyrrolidinyl)-Sulfonamide Derivatives for Use as Factor Xa Inhibitors
JP2002539210A (ja) 置換された芳香族アミジン誘導体およびこれを含有する医薬組成物
JPWO1999047503A1 (ja) アミノイソキノリン誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090602